---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-22-000021"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:54:55.959061+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs Q2 net loss $27.4M; cash runway into H2 2024; SL-172154 combo trials starting

## Summary
- Cash and equivalents $214.2M (Dec 2021: $268.8M); operations funded into second half of 2024.
- Net loss $27.4M ($0.65/share) vs $23.6M ($0.56) in Q2 2021; R&D expense rose to $23.0M from $14.9M.
- SL-172154 dose escalation in ovarian cancer reached 10.0 mg/kg; combo with liposomal doxorubicin starts Q3 2022.
- Phase 1A/B of SL-172154 in AML/HR-MDS enrolling; initial monotherapy and combo data expected 1H 2023.
- New clinical candidate from ARC or GADLEN platform expected to be announced in second half of 2022.

## SEC filing metadata
- accession: 0001680367-22-000021
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036722000021/0001680367-22-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036722000021/sttk-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-22-000021
- JSON: https://secwatch.observer/filing/0001680367-22-000021.json
- Plain text: https://secwatch.observer/filing/0001680367-22-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.